Member Info for Saint68

Weren't you having a go at people using bad language a few weeks ago Orchy (aka VLP) ?

Bella - are you suggesting they dumb down their presentations ? If so, that's the most ridiculous comment I've heard on here for a while.

@del929 - in normal circumstances I'd agree that giving away 95% is not good business but we are not in normal times. We have been told there is a real chance that WK could be nationalised so the sale has been forced upon us. I'd rathe have $9m than nothing tbh. If CS has said we're funded until 2027 then I'm inclined to believe him so have voted yes to both resolutions.

From Grok :

United States (USPTO – Technology Center 1600: Biotechnology and Organic Chemistry)

• Biotech applications are examined in TC 1600, which consistently shows higher pendency than other areas.

• As of early 2026 (reflecting FY2025 data), overall USPTO first office action pendency is around 22–26 months, with traditional total pendency (filing to grant/abandonment, excluding RCEs) at approximately 26–30 months.

• TC 1600 experiences longer delays due to backlogs, examiner expertise needs, and issues like subject matter eligibility (101 rejections) or enablement.

• Recent challenges (hiring freezes, workforce changes in 2025) have increased pendency across TCs, with TC 1600 highlighted as one of the most affected.

• Expedited options (Track One, PPH) can reduce this to 12 months or less.

Europe (European Patent Office – EPO)

• Biotechnology falls under fields like pharmaceuticals and organic chemistry, where examination is rigorous.

• Average grant procedure remains 3–5 years (36–60 months) from filing, with biotech often on the longer end due to complexity and potential oppositions (post-grant).

• No major recent changes reported specifically shortening biotech timelines; overall EPO pendency stable.

... and we're currently 9% up so what's your point ?

Another one week old Warrior joins the other numpties in the bin.

You need to sign up with Investor Meet

LLC KS Logistics (Smolensk, ИНН 6700010196; ОГРН 1236700018191) is 100% owned by Alexander Vladimirovich Morozov and directed by Mikhail Vasilievich Bordik. [eu-prod.as...rosoft.com], [mordorinte...igence.com]

This is the buyer of Eurasia Mining PLC’s West Kytlim operations (Urals) for ~RUB 671.2 million (≈ USD 9 million), with staged payments subject to license conditions. [inndex.ru], [audit-it.ru], [zachestnyibiznes.ru]

Dickie - from the RNS “ In addition, Kosvinsky Kamen will transfer the Travyanaya licence to the Group as part of the transaction - i.e., Eurasia will retain this licence following Completion.”

Would help if you read the whole thing before gobbing off 🤦🏻‍♂️

Merry Xmas and a prosperous New Year to all genuine lth.

Will or would - same meaning in the context in which it was written. Either way, don't think it will happen based on mining volume. Hopefully we'll get a sale dividend soon though...

Monkey - why do you say WK will pay us an annual dividend ? My understanding is that dividends are paid on nett profit and only if we have excess cash on the books. I can't see us being in that position for years. If we progress to mining, profit will need to be sunk back into the business. I thought the dividend was only based on a sale of the company and only on 80% of the nett profit.

Harry - why would they need to do a reverse split / consolidation to raise money (not that I think they will). I think the next major injection of cash will come from a partnership or licensing deal.

..and I’m not having a go at you for calling out the moron, I’m having a go for your slating of a share I have an interest in. Get over yourself and not everything is a conspiracy..

JHFH - let’s just address some of your comments :

“For the record? IMO you’re trading Hemo” incorrect and out of the 2 of us, you’ve sold more than I have.

“and your quite happy to have Alde here” - you cannot be serious. I’m one of the only ones here that have binned the twat and have urged others to do the same. You on the other hand cannot seem to ignore him, despite repeated calls by many for you to do so. Using your logic that suggests they you’re happy for him to be here.

“and your currently out of hemo hoping for this mysterious 5.6m discount placing from peterhouse to buy back.” - incorrect again and more than happy to with my current holding.

As far as the moron being my mate - that’s a laughable statement and you know it.

If I read someone posting nonsense about a share I’m invested in, I will call them on it - hence my replies to you. If you don’t want to hear it then stop posting your nonsense assumptions as fact.

I’m in here with the view of not selling anything until I hear more about CBR.

JHFH - you’re continually quoting Avacta in your posts so not sure how you can say you’re not.

Dog of a share 😂😂.

“ I know perfectly well what they have and you and I both know they are hoping to IMPROVE chemotherapy.” - please give us your comments on the new data on AVA6103 then. You know, then one showing 22 out of 24 complete responses in pre clinical testing with Exatecan. You’ll know that FAP expression is higher in humans than in mice so human results expected to be better.

“ If you want me to never mention Avct again then speak to Aldermoron” - ffs, how many times do I have to tell you that he’s in the bin so have no idea what tripe he’s spouting and I have no intention of conversing with him.

Also quoting financials when we’ve had nearly 100% dilution here since the consolidation is a bit rich don’t you think ?Consolidation that you were preaching to everyone would transform the company - and yet here we are 1.5p in old money.

@del - your wasting your breath on that twat. Bin him and save yourself the hassle.

JHFH - I won’t point out some of your inaccuracies just yet but you may wish you didn’t post some of them in the next few months. Stick to what you know about Hemo and leave the other share to those that know better.

Complete responses is huge news and it wasn’t just a one off !

No bad news - watch the recording of the webinar and decide for yourself.